Relay Therapeutics Inc
NASDAQ:RLAY
Relay Therapeutics Inc
NASDAQ:RLAY
Price:
7.06 USD
0.28%
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
RLAY
stock under the Base Case scenario is
0.44
USD.
Compared to the current market price of 7.06 USD,
Relay Therapeutics Inc
is
Overvalued by 94%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RLAY
Relative Value
Base Case
0.44
USD
Overvaluation 94%
Valuation Multiples
Multiples Across Competitors
RLAY Competitors Multiples
Relay Therapeutics Inc Competitors
Relay Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
934m USD | 15.3 | -1.6 | -0.3 | -0.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.1B USD | 5.3 | 59.8 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104.8B USD | 10.7 | 29.1 | 23.2 | 24.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 169.1 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.2 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
